NATCO Pharma Limited (BSE: 524816 | NSE: NATCOPHARM) has received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market generic Semaglutide Injection in India. The company has announced that the product will be launched in the domestic market in March 2026, marking its entry into one of the fastest-growing segments in diabetes treatment.
Semaglutide is indicated for the treatment of adults with insufficiently controlled Type 2 diabetes mellitus and is prescribed as an adjunct to diet and exercise. With diabetes cases continuing to rise across India, the approval is expected to improve accessibility to advanced GLP-1-based therapies at a potentially more affordable cost.
Headquartered in Hyderabad, NATCO Pharma Limited develops, manufactures and distributes generic and branded pharmaceuticals, specialty medicines, active pharmaceutical ingredients and crop protection products. The company is known for its strong research-driven approach and has established itself as a leading oncology player in the domestic targeted therapies market. It also focuses on limited-competition molecules in the United States, strengthening its presence in regulated markets.
NATCO operates nine manufacturing facilities and two R&D centers in India. Its plants are approved by leading regulatory authorities including the U.S. FDA, Brazil’s ANVISA, Health Canada and the WHO. The company supplies products to more than 50 global markets, underlining its strong international footprint.